Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): analysis of the LINKER-MM1 study

被引：0

作者：

Dhodapkar, Madhav ^{[1
]}

Bumma, Naresh ^{[2
]}

Richter, Joshua ^{[3
]}

Lee, Hans ^{[4
]}

Hoffman, James ^{[5
]}

Suvannasankha, Attaya ^{[6
,7
]}

Lentzsch, Suzanne ^{[8
]}

Shah, Mansi ^{[9
]}

Zonder, Jeffrey ^{[10
]}

Baz, Rachid ^{[11
]}

Wu, Ka Lung ^{[12
]}

Pianko, Matthew ^{[13
]}

Silbermann, Rebecca ^{[14
]}

Min, Chang-Ki ^{[15
]}

Vekemans, Marie-Christiane Madeleine ^{[16
]}

Munder, Markus ^{[17
]}

Byun, Ja Min ^{[18
]}

Martinez Lopez, Joaquin ^{[19
]}

DeVeaux, Michelle ^{[20
]}

Lorenc, Karen Rodriguez ^{[20
]}

Kroog, Glenn ^{[20
]}

Houvras, Yariv ^{[20
]}

Jagannath, Sundar ^{[1
,21
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA

[3] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[5] Univ Miami Hlth Syst, Miami, FL USA

[6] Univ Indianapolis, Simon Canc Ctr, Indianapolis, IN USA

[7] Roudebush VAMC, Indianapolis, IN USA

[8] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[9] Columbia Univ, Med Ctr, New York, NY USA

[10] Karmanos Canc Inst, Detroit, MI USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] ZNA Stuivenberg, Dept Hematol, Antwerp, Belgium

[13] Univ Michigan, Rogel Canc Ctr, Sch Med, Ann Arbor, MI USA

[14] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[15] Seoul St Marys Hosp, Seoul, South Korea

[16] Univ Catholique Louvain UCLouvain, Dept Internal Med, Brussels, Belgium

[17] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, Mainz, Germany

[18] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea

[19] Univ Complutense, Hosp Univ 12 octubre, CNIO, Madrid, Spain

[20] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[21] Mt Sinai Med Ctr, New York, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-247

引用

页码：S172 / S172

页数：1

共 50 条

[41] Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis
Jakubowiak, Andrzej
Usmani, Saad Z.
Berdeja, Jesus G.
Agha, Mounzer
Cohen, Adam D.
Hari, Parameswaran
Schecter, Jordan M.
Madduri, Deepu
Yeh, Tzu-Min
Olyslager, Yunsi
Banerjee, Arnob
Jackson, Carolyn C.
Allred, Alicia
Zudaire, Enrique
Deraedt, William
Zhou, Changwei
Geng, Dong
Pacaud, Lida
Lin, Yi
Martin, Thomas
Jagannath, Sundar
BLOOD, 2021, 138
[42] Iberdomide (IBER) plus dexamethasone (DEX) in patients with relapsed/refractory multiple myeloma (RRMM): a safety analysis from the CC-220-MM-001 trial
van de Donk, Niels
White, Darrell
Lipe, Brea
Khan, Abdullah
Niesvizky, Ruben
Oriol, Albert
Mesa, Mercedes Gironella
Anwer, Faiz
Bhutani, Manisha
McClune, Brian
Singhal, Seema
Cheng, Yiming
Hamada, Izumi
Jin, Kexin
Solomon, Thomas
Hong, Kevin
Amin, Alpesh
Maciag, Paulo
Lonial, Sagar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S214 - S215
[43] Mezagitamab Induces Immunomodulatory Effect in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Abadier, Michael
Estevam, Jose
Berg, Deborah
Fedyk, Eric Robert
BLOOD, 2020, 136
[44] POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDE
Gomez, Hernando Marta
Gironella, Merce
Abella, Eugenia
Cabezudo, Elena
Motllo, Cristina
Garcia, Antoni
Sarra, Josep
Mostacedo, Silvia
Granell, Miquel
Rosinol, Laura
HAEMATOLOGICA, 2020, 105 : 13 - 14
[45] A single-center treatment sequencing analysis in patients with relapsed/refractory multiple myeloma (RRMM)
Kumar, Swarup
Clark, Jackson
Alvarez-Soto, Alvaro
El Warrak, Samantha
Kumar, Shruthi
Braish, Julie
Reddy, Aswanth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S190 - S191
[46] Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Ailawadhi, Sikander
Stiff, Patrick J.
Ibrahim, Emad
Vallurupalli, Anusha
Cull, Elizabeth H.
Green, Damian J.
Oliver, Kate
Longcor, Jarrod
BLOOD, 2019, 134
[47] Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma
Berenson, James R.
Martinez, Daisy
Safaie, Tahmineh
Silagan, Noemi
To, Jennifer
Spektor, Tanya M.
Forouzan, Eli
Swift, Regina
Eades, Benjamin
Eshaghian, Shahrooz
Schwartz, Gary
Boccia, Ralph V.
Yang, Honghao H.
Moezi, Mehdi M.
Lim, Stephen
Vescio, Robert
BLOOD, 2021, 138
[48] Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
Suvannasankha, Attaya
Bahlis, Nizar
Trudel, Suzanne
Weisel, Katja
Koenecke, Christian
Oriol, Albert
Voorhees, Peter M.
Alonso, Aranzazu A.
Callander, Natalie S.
Mateos, Maria-Victoria
Reddy, Nishitha
Hakim, Shawn
Lamacchia, John
Patel, Nashita
Williams, Danae
Jewell, Roxanne. C.
Zhou, Xiangdong
Gupta, Ira
Opalinska, Joanna
Nooka, Ajay K.
CANCER, 2024, 130 (15) : 2629 - 2641
[49] Treatment patterns among patients with relapsed/refractory multiple myeloma (RRMM) in Taiwan
Huang, Jeffrey Shang-Yi
Wang, Ming-Chung
Yeh, Su-Peng
Chen, Tsai-Yun
Teng, Chieh-Lin Jerry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S188 - S189
[50] Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Ailawadhi, Sikander
DerSarkissian, Maral
Duh, Mei Sheng
Lafeuille, Marie-Helene
Posner, George
Ralston, Stephen
Zagadailov, Erin
Ba-Mancini, Abbie
Rifkin, Robert M.
BLOOD, 2017, 130

← 1 2 3 4 5 →